首页 > 最新文献

JTO Clinical and Research Reports最新文献

英文 中文
Comparing Three Different Anti–Programmed Death-Ligand 1 Antibodies in Immunohistochemical Evaluation of Combined Chemoimmunotherapy Response in Patients With NSCLC: A Prospective Study 比较三种不同的抗程序性死亡配体 1 抗体对 NSCLC 患者联合化疗免疫反应的免疫组化评估:一项前瞻性研究
Q3 Medicine Pub Date : 2024-03-01 DOI: 10.1016/j.jtocrr.2024.100644
Yuki Katayama MD, PhD , Tadaaki Yamada MD, PhD , Kenji Morimoto MD, PhD , Hiroyuki Fujii MD , Satomi Morita MD, PhD , Keiko Tanimura MD, PhD , Takayuki Takeda MD, PhD , Asuka Okada MD, PhD , Shinsuke Shiotsu MD, PhD , Yusuke Chihara MD, PhD , Osamu Hiranuma MD , Takahiro Yamada MD, PhD , Takahiro Ota MD, PhD , Taishi Harada MD , Isao Hasegawa MD, PhD , Masahiro Iwasaku MD, PhD , Shinsaku Tokuda MD, PhD , Noriyuki Tanaka MD, PhD , Aya Miyagawa-Hayashino MD, PhD , Koichi Takayama MD, PhD

Introduction

Multiple programmed death-ligand 1 (PD-L1) immunohistochemistry assays performed using different antibodies including DAKO 22C3, DAKO 28-8, and Ventana SP142 PD-L1—predictive markers for response to various immune checkpoint inhibitors in NSCLC—have been approved in several countries. The differences in multiple PD-L1 immunohistochemistry assay results in predicting the therapeutic response to combined chemoimmunotherapy in patients with NSCLC remain unclear.

Methods

In this multicenter prospective observational study, we monitored 70 patients with advanced NSCLC treated with combined chemoimmunotherapy at 10 institutions in Japan. The expression of PD-L1 in pretreatment tumors was evaluated using the 22C3, 28-8, and SP142 assays in all patients.

Results

The PD-L1 level in tumor cells determined using the 22C3 assay was the highest among the three assays performed with different antibodies. According to the 22C3 assay results, the PD-L1 tumor proportion score greater than or equal to 50% group had a significantly longer progression-free survival period than the PD-L1 tumor proportion score less than 50% group. Nevertheless, the other assays did not reveal remarkable differences in the objective response rate or progression-free survival.

Conclusions

In our study, PD-L1 expression determined using the 22C3 assay was more correlated with the therapeutic response of patients with NSCLC treated with combined chemoimmunotherapy than that determined using the 28-8 and SP142 assays. Therefore, the 22C3 assay may be useful for clinical decision-making for patients with NSCLC treated with combined chemoimmunotherapy. Trial registration number: UMIN 000043958.

导言使用不同抗体(包括DAKO 22C3、DAKO 28-8和Ventana SP142)进行的多种程序性死亡配体1(PD-L1)免疫组化检测--NSCLC患者对各种免疫检查点抑制剂反应的预测标志物--已在多个国家获得批准。在这项多中心前瞻性观察研究中,我们对日本 10 家机构的 70 例接受联合化疗免疫治疗的晚期 NSCLC 患者进行了监测。结果使用 22C3 检测法测定的肿瘤细胞中的 PD-L1 水平是使用不同抗体进行的三种检测法中最高的。根据 22C3 检测结果,PD-L1 肿瘤比例大于或等于 50%组的无进展生存期明显长于 PD-L1 肿瘤比例小于 50%组。结论 在我们的研究中,与使用 28-8 和 SP142 检测方法相比,使用 22C3 检测方法测定的 PD-L1 表达与接受联合化疗免疫疗法的 NSCLC 患者的治疗反应更相关。因此,22C3测定可能有助于接受联合化疗免疫疗法的NSCLC患者的临床决策。试验注册号:umin 000043958。
{"title":"Comparing Three Different Anti–Programmed Death-Ligand 1 Antibodies in Immunohistochemical Evaluation of Combined Chemoimmunotherapy Response in Patients With NSCLC: A Prospective Study","authors":"Yuki Katayama MD, PhD ,&nbsp;Tadaaki Yamada MD, PhD ,&nbsp;Kenji Morimoto MD, PhD ,&nbsp;Hiroyuki Fujii MD ,&nbsp;Satomi Morita MD, PhD ,&nbsp;Keiko Tanimura MD, PhD ,&nbsp;Takayuki Takeda MD, PhD ,&nbsp;Asuka Okada MD, PhD ,&nbsp;Shinsuke Shiotsu MD, PhD ,&nbsp;Yusuke Chihara MD, PhD ,&nbsp;Osamu Hiranuma MD ,&nbsp;Takahiro Yamada MD, PhD ,&nbsp;Takahiro Ota MD, PhD ,&nbsp;Taishi Harada MD ,&nbsp;Isao Hasegawa MD, PhD ,&nbsp;Masahiro Iwasaku MD, PhD ,&nbsp;Shinsaku Tokuda MD, PhD ,&nbsp;Noriyuki Tanaka MD, PhD ,&nbsp;Aya Miyagawa-Hayashino MD, PhD ,&nbsp;Koichi Takayama MD, PhD","doi":"10.1016/j.jtocrr.2024.100644","DOIUrl":"https://doi.org/10.1016/j.jtocrr.2024.100644","url":null,"abstract":"<div><h3>Introduction</h3><p>Multiple programmed death-ligand 1 (PD-L1) immunohistochemistry assays performed using different antibodies including DAKO 22C3, DAKO 28-8, and Ventana SP142 PD-L1—predictive markers for response to various immune checkpoint inhibitors in NSCLC—have been approved in several countries. The differences in multiple PD-L1 immunohistochemistry assay results in predicting the therapeutic response to combined chemoimmunotherapy in patients with NSCLC remain unclear.</p></div><div><h3>Methods</h3><p>In this multicenter prospective observational study, we monitored 70 patients with advanced NSCLC treated with combined chemoimmunotherapy at 10 institutions in Japan. The expression of PD-L1 in pretreatment tumors was evaluated using the 22C3, 28-8, and SP142 assays in all patients.</p></div><div><h3>Results</h3><p>The PD-L1 level in tumor cells determined using the 22C3 assay was the highest among the three assays performed with different antibodies. According to the 22C3 assay results, the PD-L1 tumor proportion score greater than or equal to 50% group had a significantly longer progression-free survival period than the PD-L1 tumor proportion score less than 50% group. Nevertheless, the other assays did not reveal remarkable differences in the objective response rate or progression-free survival.</p></div><div><h3>Conclusions</h3><p>In our study, PD-L1 expression determined using the 22C3 assay was more correlated with the therapeutic response of patients with NSCLC treated with combined chemoimmunotherapy than that determined using the 28-8 and SP142 assays. Therefore, the 22C3 assay may be useful for clinical decision-making for patients with NSCLC treated with combined chemoimmunotherapy. Trial registration number: UMIN 000043958.</p></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666364324000146/pdfft?md5=6b465a7124f91c9ea13f64ca0b06a8ae&pid=1-s2.0-S2666364324000146-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140015276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biomarker Testing, Targeted Therapy and Clinical Trial Participation by Race Among Patients With Lung Cancer: A Real-World Medicaid Database Study 按种族划分的肺癌患者生物标记物检测、靶向治疗和临床试验参与情况:真实世界医疗补助数据库研究
Q3 Medicine Pub Date : 2024-03-01 DOI: 10.1016/j.jtocrr.2024.100643
Debora S. Bruno MD, MS , Xiaohong Li MPH , Lisa M. Hess PhD

Introduction

Biomarker testing in oncology is fundamental for targeted therapy use and clinical trial participation. Factors contributing to previously identified racial disparities in biomarker testing remain unclear. This study investigated biomarker testing, clinical trial participation, and targeted therapy by race among patients with metastatic lung cancer with Medicaid coverage in the United States.

Methods

The Merative MarketScan Medicaid claims database was used for this study to identify patients diagnosed with having metastatic lung cancer between 2017 and 2019 with at least 121 days of follow-up. Racial differences in biomarker testing, clinical trial enrollment, and targeted therapy use were analyzed using chi-square/t tests followed by logistic regression for confounding covariates.

Results

A total of 3845 patients were eligible. A total of 970 (25.2%) patients included in this study were Black. Biomarker testing was observed among 57.0%, targeted therapy among 4.6%, and 2.6% of the study cohort had evidence of clinical trial participation. No significant disparities between Black and White races were identified. Younger age and metastatic disease at initial diagnosis were the strongest independent factors associated with increased biomarker testing. Biomarker testing was positively associated with targeted therapy use (OR = 1.69, p = 0.005).

Conclusions

Patients with metastatic lung cancer with Medicaid coverage were found to have exceedingly low biomarker testing rates; only 57% had evidence of any biomarker testing. Although no consistent differences between Black and White races were identified, this study calls attention to care experienced by socioeconomically disadvantaged patients with metastatic lung cancer in the United States.

导言 肿瘤学中的生物标记物检测是使用靶向治疗和参与临床试验的基础。目前尚不清楚造成生物标记物检测中种族差异的因素。本研究调查了美国医疗补助(Medicaid)覆盖范围内的转移性肺癌患者的生物标记物检测、临床试验参与和靶向治疗的种族差异。方法本研究使用了Merative MarketScan医疗补助报销数据库,以确定2017年至2019年期间被诊断为转移性肺癌且随访至少121天的患者。使用chi-square/t检验分析了生物标志物检测、临床试验入组和靶向治疗使用方面的种族差异,随后使用逻辑回归分析了混杂协变量。共有 970 名(25.2%)患者为黑人。57.0%的患者接受了生物标记物检测,4.6%的患者接受了靶向治疗,2.6%的患者有参与临床试验的证据。没有发现黑人和白人之间存在明显差异。初诊时年龄较小和转移性疾病是与生物标志物检测增加相关的最重要的独立因素。生物标志物检测与靶向治疗的使用呈正相关(OR = 1.69,p = 0.005)。结论发现,享有医疗补助的转移性肺癌患者的生物标志物检测率极低;只有 57% 的患者有证据表明进行过任何生物标志物检测。虽然没有发现黑人和白人之间存在一致的差异,但这项研究呼吁人们关注美国社会经济条件较差的转移性肺癌患者所经历的护理。
{"title":"Biomarker Testing, Targeted Therapy and Clinical Trial Participation by Race Among Patients With Lung Cancer: A Real-World Medicaid Database Study","authors":"Debora S. Bruno MD, MS ,&nbsp;Xiaohong Li MPH ,&nbsp;Lisa M. Hess PhD","doi":"10.1016/j.jtocrr.2024.100643","DOIUrl":"10.1016/j.jtocrr.2024.100643","url":null,"abstract":"<div><h3>Introduction</h3><p>Biomarker testing in oncology is fundamental for targeted therapy use and clinical trial participation. Factors contributing to previously identified racial disparities in biomarker testing remain unclear. This study investigated biomarker testing, clinical trial participation, and targeted therapy by race among patients with metastatic lung cancer with Medicaid coverage in the United States.</p></div><div><h3>Methods</h3><p>The Merative MarketScan Medicaid claims database was used for this study to identify patients diagnosed with having metastatic lung cancer between 2017 and 2019 with at least 121 days of follow-up. Racial differences in biomarker testing, clinical trial enrollment, and targeted therapy use were analyzed using chi-square/<em>t</em> tests followed by logistic regression for confounding covariates.</p></div><div><h3>Results</h3><p>A total of 3845 patients were eligible. A total of 970 (25.2%) patients included in this study were Black. Biomarker testing was observed among 57.0%, targeted therapy among 4.6%, and 2.6% of the study cohort had evidence of clinical trial participation. No significant disparities between Black and White races were identified. Younger age and metastatic disease at initial diagnosis were the strongest independent factors associated with increased biomarker testing. Biomarker testing was positively associated with targeted therapy use (OR = 1.69, <em>p</em> = 0.005).</p></div><div><h3>Conclusions</h3><p>Patients with metastatic lung cancer with Medicaid coverage were found to have exceedingly low biomarker testing rates; only 57% had evidence of any biomarker testing. Although no consistent differences between Black and White races were identified, this study calls attention to care experienced by socioeconomically disadvantaged patients with metastatic lung cancer in the United States.</p></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666364324000134/pdfft?md5=77600ead9f365e8eab58b497409a8a1c&pid=1-s2.0-S2666364324000134-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139826805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Benefits and Harms of Lung Cancer Screening in Individuals With Comorbidities 合并症患者进行肺癌筛查的益处和害处
Q3 Medicine Pub Date : 2024-03-01 DOI: 10.1016/j.jtocrr.2024.100635
Minal S. Kale MD, MPH , Keith Sigel MD, PhD , Arushi Arora MPH , Bart S. Ferket MD, PhD , Juan Wisnivesky MD, DrPh , Chung Yin Kong PhD

Introduction

Individuals with a history of smoking and a high risk of lung cancer often have a high prevalence of smoking-related comorbidities. The presence of these comorbidities might alter the benefit-to-harm ratio of lung cancer screening by influencing the risk of complications, quality of life, and competing risks of death. Nevertheless, individuals with chronic diseases are underrepresented in screening clinical trials. In this study, we use microsimulation modeling to determine the impact of chronic diseases on lung cancer benefits and harms.

Methods

We extended a validated lung cancer screening microsimulation model that comprehensively recapitulates an individual’s lung cancer development, progression, detection, follow-up, treatment, and survival. We parameterized the model to reflect the impact of chronic diseases on complications from invasive testing, quality of life, and mortality in individuals in five-year age categories between the ages of 50 and 80 years. Outcomes included life-years (LY) gained per 100,000 in patients with chronic obstructive pulmonary disease, diabetes mellitus, heart disease, and history of stroke compared with screening-eligible individuals without comorbidities.

Results

Among individuals between the ages of 50 and 54 years, we found that the presence of a comorbidity altered the LY gained from screening per 100,000 individuals depending on the comorbidity: 4296 LY with no comorbidities; 3462 LY, 3260 LY, 3031 LY, and 3257 LY with chronic obstructive pulmonary disease, heart disease, diabetes mellitus, and stroke, respectively. We observed greater reductions in LY gained in individuals with two comorbidities; we observed similar patterns for individuals between the ages of 55 and 59 years, 60 and 64 years, 65 and 69 years, 70 and 74 years, and 75 and 80 years.

Conclusions

Comorbidities reduce LY gained from screening per 100,000 compared with no comorbidities, and our results can be used by clinicians when discussing the benefits and harms of screening in their patients with comorbidities.

导言有吸烟史和肺癌高风险的人往往有较高的吸烟相关合并症。这些合并症的存在可能会影响并发症风险、生活质量和死亡风险,从而改变肺癌筛查的利弊比。然而,在筛查临床试验中,慢性病患者的比例偏低。在本研究中,我们使用微观模拟模型来确定慢性病对肺癌益处和危害的影响。方法我们扩展了一个经过验证的肺癌筛查微观模拟模型,该模型全面再现了个体的肺癌发生、发展、检测、随访、治疗和生存过程。我们对模型进行了参数设置,以反映慢性疾病对侵入性检查并发症、生活质量和死亡率的影响。结果包括慢性阻塞性肺病、糖尿病、心脏病和中风病患者与无并发症的符合筛查条件者相比,每十万人获得的生命年数(LY)。结果我们发现,在 50 至 54 岁的人群中,合并症的存在会根据合并症的不同而改变每 10 万人从筛查中获得的收益:无合并症者为 4296 LY;患有慢性阻塞性肺病、心脏病、糖尿病和中风者分别为 3462 LY、3260 LY、3031 LY 和 3257 LY。结论与无合并症相比,合并症会降低每 10 万人从筛查中获得的 LY,临床医生在讨论对合并症患者进行筛查的益处和害处时可以参考我们的结果。
{"title":"The Benefits and Harms of Lung Cancer Screening in Individuals With Comorbidities","authors":"Minal S. Kale MD, MPH ,&nbsp;Keith Sigel MD, PhD ,&nbsp;Arushi Arora MPH ,&nbsp;Bart S. Ferket MD, PhD ,&nbsp;Juan Wisnivesky MD, DrPh ,&nbsp;Chung Yin Kong PhD","doi":"10.1016/j.jtocrr.2024.100635","DOIUrl":"10.1016/j.jtocrr.2024.100635","url":null,"abstract":"<div><h3>Introduction</h3><p>Individuals with a history of smoking and a high risk of lung cancer often have a high prevalence of smoking-related comorbidities. The presence of these comorbidities might alter the benefit-to-harm ratio of lung cancer screening by influencing the risk of complications, quality of life, and competing risks of death. Nevertheless, individuals with chronic diseases are underrepresented in screening clinical trials. In this study, we use microsimulation modeling to determine the impact of chronic diseases on lung cancer benefits and harms.</p></div><div><h3>Methods</h3><p>We extended a validated lung cancer screening microsimulation model that comprehensively recapitulates an individual’s lung cancer development, progression, detection, follow-up, treatment, and survival. We parameterized the model to reflect the impact of chronic diseases on complications from invasive testing, quality of life, and mortality in individuals in five-year age categories between the ages of 50 and 80 years. Outcomes included life-years (LY) gained per 100,000 in patients with chronic obstructive pulmonary disease, diabetes mellitus, heart disease, and history of stroke compared with screening-eligible individuals without comorbidities.</p></div><div><h3>Results</h3><p>Among individuals between the ages of 50 and 54 years, we found that the presence of a comorbidity altered the LY gained from screening per 100,000 individuals depending on the comorbidity: 4296 LY with no comorbidities; 3462 LY, 3260 LY, 3031 LY, and 3257 LY with chronic obstructive pulmonary disease, heart disease, diabetes mellitus, and stroke, respectively. We observed greater reductions in LY gained in individuals with two comorbidities; we observed similar patterns for individuals between the ages of 55 and 59 years, 60 and 64 years, 65 and 69 years, 70 and 74 years, and 75 and 80 years.</p></div><div><h3>Conclusions</h3><p>Comorbidities reduce LY gained from screening per 100,000 compared with no comorbidities, and our results can be used by clinicians when discussing the benefits and harms of screening in their patients with comorbidities.</p></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666364324000055/pdfft?md5=0b627dc63eb51da85b2b89dffb3e06a2&pid=1-s2.0-S2666364324000055-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139539906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rapid Response to Lenvatinib and Disease Flare After Discontinuation in a Patient With Thymic Carcinoma Harboring KIT Exon 11 Mutation: A Case Report 一名携带 KIT 外显子 11 突变的胸腺癌患者对伦伐替尼的快速反应和停药后的疾病复发:病例报告
Q3 Medicine Pub Date : 2024-02-28 DOI: 10.1016/j.jtocrr.2024.100657
Masahiro Torasawa MD , Tatsuya Yoshida MD, PhD , Kouya Shiraishi PhD , Naoko Goto BS , Toshihide Ueno PhD , Hitoshi Ichikawa MD, PhD , Shigehiro Yagishita MD, PhD , Shinji Kohsaka MD, PhD , Yasushi Goto MD, PhD , Yasushi Yatabe MD, PhD , Akinobu Hamada PhD , Hiroyuki Mano MD, PhD , Yuichiro Ohe MD, PhD

Lenvatinib, a multitarget tyrosine kinase inhibitor for c-Kit and other kinases, has exhibited promising efficacy in treating advanced or metastatic thymic carcinoma (TC). Here, we present the case of a patient with metastatic TC harboring a KIT exon 11 deletion and amplification. The patient exhibited a remarkable response to lenvatinib but experienced rapid disease progression after discontinuation of lenvatinib, referred to as a “disease flare.” This case report indicates that KIT mutations and amplification can predict lenvatinib response in patients with TC. However, in such cases, there might be a risk of disease flares after lenvatinib discontinuation.

伦伐替尼是一种针对c-Kit和其他激酶的多靶点酪氨酸激酶抑制剂,在治疗晚期或转移性胸腺癌(TC)方面具有良好的疗效。在此,我们介绍一例携带 KIT 第 11 号外显子缺失和扩增的转移性胸腺癌患者。该患者对来伐替尼有明显反应,但停用来伐替尼后疾病迅速进展,被称为 "疾病爆发"。该病例报告表明,KIT突变和扩增可预测来伐替尼对TC患者的反应。然而,在这种情况下,停用来伐替尼后可能会出现疾病复发的风险。
{"title":"Rapid Response to Lenvatinib and Disease Flare After Discontinuation in a Patient With Thymic Carcinoma Harboring KIT Exon 11 Mutation: A Case Report","authors":"Masahiro Torasawa MD ,&nbsp;Tatsuya Yoshida MD, PhD ,&nbsp;Kouya Shiraishi PhD ,&nbsp;Naoko Goto BS ,&nbsp;Toshihide Ueno PhD ,&nbsp;Hitoshi Ichikawa MD, PhD ,&nbsp;Shigehiro Yagishita MD, PhD ,&nbsp;Shinji Kohsaka MD, PhD ,&nbsp;Yasushi Goto MD, PhD ,&nbsp;Yasushi Yatabe MD, PhD ,&nbsp;Akinobu Hamada PhD ,&nbsp;Hiroyuki Mano MD, PhD ,&nbsp;Yuichiro Ohe MD, PhD","doi":"10.1016/j.jtocrr.2024.100657","DOIUrl":"https://doi.org/10.1016/j.jtocrr.2024.100657","url":null,"abstract":"<div><p>Lenvatinib, a multitarget tyrosine kinase inhibitor for c-Kit and other kinases, has exhibited promising efficacy in treating advanced or metastatic thymic carcinoma (TC). Here, we present the case of a patient with metastatic TC harboring a <em>KIT</em> exon 11 deletion and amplification. The patient exhibited a remarkable response to lenvatinib but experienced rapid disease progression after discontinuation of lenvatinib, referred to as a “disease flare.” This case report indicates that <em>KIT</em> mutations and amplification can predict lenvatinib response in patients with TC. However, in such cases, there might be a risk of disease flares after lenvatinib discontinuation.</p></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666364324000274/pdfft?md5=b9ec22f6643d5497789d13c673ed5b47&pid=1-s2.0-S2666364324000274-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140163115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
RET Fusion Testing in Patients With NSCLC: The RETING Study 非小细胞肺癌患者的 RET 融合检测:RETING 研究
Q3 Medicine Pub Date : 2024-02-20 DOI: 10.1016/j.jtocrr.2024.100653
Esther Conde MD, PhD , Susana Hernandez PhD , Jose Luis Rodriguez Carrillo MD , Rebeca Martinez APT , Marta Alonso APT , Daniel Curto MD , Beatriz Jimenez MD , Alejandra Caminoa MD, PhD , Amparo Benito MD , Pilar Garrido MD, PhD , Sergi Clave PhD , Edurne Arriola MD, PhD , Isabel Esteban-Rodriguez MD, PhD , Javier De Castro MD, PhD , Irene Sansano MD , Enriqueta Felip MD, PhD , Federico Rojo MD, PhD , Manuel Dómine MD, PhD , Ihab Abdulkader MD, PhD , Jorge Garcia-Gonzalez MD , Fernando Lopez-Rios MD, PhD

Introduction

RET inhibitors with impressive overall response rates are now available for patients with NSCLC, yet the identification of RET fusions remains a difficult challenge. Most guidelines encourage the upfront use of next-generation sequencing (NGS), or alternatively, fluorescence in situ hybridization (FISH) or reverse transcriptase-polymerase chain reaction (RT-PCR) when NGS is not possible or available. Taken together, the suboptimal performance of single-analyte assays to detect RET fusions, although consistent with the notion of encouraging universal NGS, is currently widening some of the clinical practice gaps in the implementation of predictive biomarkers in patients with advanced NSCLC.

Methods

This situation prompted us to evaluate several RET assays in a large multicenter cohort of RET fusion–positive NSCLC (n = 38) to obtain real-world data. In addition to RNA-based NGS (the criterion standard method), all positive specimens underwent break-apart RET FISH with two different assays and were also tested by an RT-PCR assay.

Results

The most common RET partners were KIF5B (78.9%), followed by CCDC6 (15.8%). The two RET NGS-positive but FISH-negative samples contained a KIF5B(15)-RET(12) fusion. The three RET fusions not identified with RT-PCR were AKAP13(35)-RET(12), KIF5B(24)-RET(9) and KIF5B(24)-RET(11). All three false-negative RT-PCR cases were FISH-positive, exhibited a typical break-apart pattern, and contained a very high number of positive tumor cells with both FISH assays. Signet ring cells, psammoma bodies, and pleomorphic features were frequently observed (in 34.2%, 39.5%, and 39.5% of tumors, respectively).

Conclusions

In-depth knowledge of the advantages and disadvantages of the different RET testing methodologies could help clinical and molecular tumor boards implement and maintain sensible algorithms for the rapid and effective detection of RET fusions in patients with NSCLC. The likelihood of RET false-negative results with both FISH and RT-PCR reinforces the need for upfront NGS in patients with NSCLC.

目前,可用于 NSCLC 患者的导入 RET 抑制剂的总体反应率令人印象深刻,但 RET 融合的鉴定仍是一项艰巨的挑战。大多数指南都鼓励在前期使用新一代测序(NGS),或者在无法使用 NGS 时使用荧光原位杂交(FISH)或反转录聚合酶链反应(RT-PCR)。这种情况促使我们在 RET 融合阳性 NSCLC(n = 38)的大型多中心队列中评估了几种 RET 检测方法,以获得真实世界的数据。除了基于 RNA 的 NGS(标准方法)外,所有阳性标本都接受了两种不同检测方法的 RET FISH 检测,还接受了 RT-PCR 检测。结果最常见的 RET 伴侣是 KIF5B(78.9%),其次是 CCDC6(15.8%)。两个 RET NGS 阳性但 FISH 阴性的样本含有 KIF5B(15)-RET(12) 融合。RT-PCR 未鉴定出的三例 RET 融合为 AKAP13(35)-RET(12)、KIF5B(24)-RET(9) 和 KIF5B(24)-RET(11)。三例 RT-PCR 假阴性病例均为 FISH 阳性,表现出典型的断裂模式,且两种 FISH 检测方法均含有大量阳性肿瘤细胞。结论深入了解不同 RET 检测方法的优缺点有助于临床和分子肿瘤委员会实施和维护合理的算法,快速有效地检测 NSCLC 患者的 RET 融合。FISH和RT-PCR都有可能出现RET假阴性结果,这加强了对NSCLC患者进行前期NGS检测的必要性。
{"title":"RET Fusion Testing in Patients With NSCLC: The RETING Study","authors":"Esther Conde MD, PhD ,&nbsp;Susana Hernandez PhD ,&nbsp;Jose Luis Rodriguez Carrillo MD ,&nbsp;Rebeca Martinez APT ,&nbsp;Marta Alonso APT ,&nbsp;Daniel Curto MD ,&nbsp;Beatriz Jimenez MD ,&nbsp;Alejandra Caminoa MD, PhD ,&nbsp;Amparo Benito MD ,&nbsp;Pilar Garrido MD, PhD ,&nbsp;Sergi Clave PhD ,&nbsp;Edurne Arriola MD, PhD ,&nbsp;Isabel Esteban-Rodriguez MD, PhD ,&nbsp;Javier De Castro MD, PhD ,&nbsp;Irene Sansano MD ,&nbsp;Enriqueta Felip MD, PhD ,&nbsp;Federico Rojo MD, PhD ,&nbsp;Manuel Dómine MD, PhD ,&nbsp;Ihab Abdulkader MD, PhD ,&nbsp;Jorge Garcia-Gonzalez MD ,&nbsp;Fernando Lopez-Rios MD, PhD","doi":"10.1016/j.jtocrr.2024.100653","DOIUrl":"https://doi.org/10.1016/j.jtocrr.2024.100653","url":null,"abstract":"<div><h3>Introduction</h3><p><em>RET</em> inhibitors with impressive overall response rates are now available for patients with NSCLC, yet the identification of <em>RET</em> fusions remains a difficult challenge. Most guidelines encourage the upfront use of next-generation sequencing (NGS), or alternatively, fluorescence in situ hybridization (FISH) or reverse transcriptase-polymerase chain reaction (RT-PCR) when NGS is not possible or available. Taken together, the suboptimal performance of single-analyte assays to detect <em>RET</em> fusions, although consistent with the notion of encouraging universal NGS, is currently widening some of the clinical practice gaps in the implementation of predictive biomarkers in patients with advanced NSCLC.</p></div><div><h3>Methods</h3><p>This situation prompted us to evaluate several <em>RET</em> assays in a large multicenter cohort of <em>RET</em> fusion–positive NSCLC (n = 38) to obtain real-world data. In addition to RNA-based NGS (the criterion standard method), all positive specimens underwent break-apart <em>RET</em> FISH with two different assays and were also tested by an RT-PCR assay.</p></div><div><h3>Results</h3><p>The most common <em>RET</em> partners were <em>KIF5B</em> (78.9%), followed by <em>CCDC6</em> (15.8%). The two <em>RET</em> NGS-positive but FISH-negative samples contained a <em>KIF5B(15)-RET(12)</em> fusion. The three <em>RET</em> fusions not identified with RT-PCR were <em>AKAP13(35)-RET(12)</em>, <em>KIF5B(24)-RET(9)</em> and <em>KIF5B(24)-RET(11)</em>. All three false-negative RT-PCR cases were FISH-positive, exhibited a typical break-apart pattern, and contained a very high number of positive tumor cells with both FISH assays. Signet ring cells, psammoma bodies, and pleomorphic features were frequently observed (in 34.2%, 39.5%, and 39.5% of tumors, respectively).</p></div><div><h3>Conclusions</h3><p>In-depth knowledge of the advantages and disadvantages of the different <em>RET</em> testing methodologies could help clinical and molecular tumor boards implement and maintain sensible algorithms for the rapid and effective detection of <em>RET</em> fusions in patients with NSCLC. The likelihood of <em>RET</em> false-negative results with both FISH and RT-PCR reinforces the need for upfront NGS in patients with NSCLC.</p></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666364324000237/pdfft?md5=1d0484197557d1fce0d0732e03259f18&pid=1-s2.0-S2666364324000237-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140141940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced EGFR-Mutated NSCLC 晚期表皮生长因子受体突变 NSCLC 患者奥希替尼血浆低浓度与脑转移灶发展的关系
Q3 Medicine Pub Date : 2024-02-20 DOI: 10.1016/j.jtocrr.2024.100656
Judith L. Gulikers MSc , G.D. Marijn Veerman MD, PhD , Merel Jebbink MD, PhD , Paul D. Kruithof PharmD , Christi M.J. Steendam MD, PhD , René J. Boosman PhD , Ron H.J. Mathijssen MD, PhD , Vivianne C.G. Tjan-Heijnen MD, PhD , Johanna H.M. Driessen PhD , Safiye Dursun MD , Egbert F. Smit MD, PhD , Anne-Marie C. Dingemans MD, PhD , Robin M.J.M. van Geel PharmD, PhD , Sander Croes PharmD, PhD , Lizza E.L. Hendriks MD, PhD

Introduction

Brain metastases (BM) are common in patients with advanced EGFR-mutated (EGFRm+) NSCLC. Despite good BM-related outcomes of osimertinib, several patients still experience intracranial progression. A possible explanation is pharmacologic failure due to low plasma trough levels (Cmin,SS) and consequently limited intracranial osimertinib exposure. We investigated the relation between osimertinib Cmin,SS and BM development or progression.

Methods

A prospective multicenter cohort study, including patients receiving osimertinib for advanced EGFRm+ NSCLC. At osimertinib start, patients were allocated to the BM or no or unknown BM cohort and were further divided into subgroups based on osimertinib Cmin,SS (low, middle, and high exposure). Cumulative incidence of BM progression or development and overall survival were determined for each group.

Results

A total of 173 patients were included, with 49 (28.3%) had baseline BM. Of these patients, 36.7% experienced BM progression, of which 16.7% in the low (<159.3 ng/mL), 40.0% in the middle, and 47.1% in the high (>270.7 ng/mL) Cmin,SS subgroups. After 12 months, the cumulative incidence of BM progression for the BM cohort was 20% (95% confidence interval [CI] 2.6–49.0), 31% (95% CI:10.6–53.9), and 31% (95% CI:10.8–54.5) per Cmin,SS subgroup, respectively. After 20 months, this was 20% (95% CI:2.6–49.0), 52% (95% CI:23.8–74.2), and 57% (95% CI:24.9–79.7), respectively. For the no or unknown BM cohort, 4.0% developed BM without differences within Cmin,SS subgroups.

Conclusions

No relation was found between osimertinib Cmin,SS and BM development or progression in patients with advanced EGFRm+ NSCLC. This suggests that systemic osimertinib exposure is not a surrogate marker for BM development or progression.

简介:脑转移(BM)是晚期表皮生长因子受体突变(EGFRm+)NSCLC 患者的常见病。尽管奥希替尼的脑转移相关疗效良好,但仍有一些患者出现颅内进展。一种可能的解释是,由于血浆低谷水平(Cmin,SS)导致药理作用失效,从而限制了颅内奥希替尼的暴露。我们研究了奥希替尼 Cmin,SS 与 BM 发生或进展之间的关系。在奥希替尼起始时,患者被分配到有骨髓或无骨髓或骨髓不明队列,并根据奥希替尼Cmin,SS(低、中、高暴露)进一步分为亚组。结果 共纳入173例患者,其中49例(28.3%)有基线骨髓瘤。在这些患者中,36.7%的患者出现骨髓瘤进展,其中低Cmin,SS亚组(<159.3 ng/mL)16.7%,中Cmin,SS亚组40.0%,高Cmin,SS亚组(>270.7 ng/mL)47.1%。12 个月后,每个 Cmin、SS 亚组的 BM 进展累积发生率分别为 20%(95% 置信区间 [CI]:2.6-49.0)、31%(95% CI:10.6-53.9)和 31%(95% CI:10.8-54.5)。20 个月后,这一比例分别为 20%(95% CI:2.6-49.0)、52%(95% CI:23.8-74.2)和 57%(95% CI:24.9-79.7)。结论 在晚期表皮生长因子受体m+ NSCLC患者中,奥希替尼Cmin,SS与表皮生长因子受体的发生或进展之间未发现任何关系。这表明,全身奥希替尼暴露并不是骨髓瘤发生或进展的替代标志物。
{"title":"Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced EGFR-Mutated NSCLC","authors":"Judith L. Gulikers MSc ,&nbsp;G.D. Marijn Veerman MD, PhD ,&nbsp;Merel Jebbink MD, PhD ,&nbsp;Paul D. Kruithof PharmD ,&nbsp;Christi M.J. Steendam MD, PhD ,&nbsp;René J. Boosman PhD ,&nbsp;Ron H.J. Mathijssen MD, PhD ,&nbsp;Vivianne C.G. Tjan-Heijnen MD, PhD ,&nbsp;Johanna H.M. Driessen PhD ,&nbsp;Safiye Dursun MD ,&nbsp;Egbert F. Smit MD, PhD ,&nbsp;Anne-Marie C. Dingemans MD, PhD ,&nbsp;Robin M.J.M. van Geel PharmD, PhD ,&nbsp;Sander Croes PharmD, PhD ,&nbsp;Lizza E.L. Hendriks MD, PhD","doi":"10.1016/j.jtocrr.2024.100656","DOIUrl":"https://doi.org/10.1016/j.jtocrr.2024.100656","url":null,"abstract":"<div><h3>Introduction</h3><p>Brain metastases (BM) are common in patients with advanced <em>EGFR</em>-mutated (<em>EGFR</em>m+) NSCLC. Despite good BM-related outcomes of osimertinib, several patients still experience intracranial progression. A possible explanation is pharmacologic failure due to low plasma trough levels (C<sub>min,SS</sub>) and consequently limited intracranial osimertinib exposure. We investigated the relation between osimertinib C<sub>min,SS</sub> and BM development or progression.</p></div><div><h3>Methods</h3><p>A prospective multicenter cohort study, including patients receiving osimertinib for advanced <em>EGFR</em>m<em>+</em> NSCLC. At osimertinib start, patients were allocated to the BM or no or unknown BM cohort and were further divided into subgroups based on osimertinib C<sub>min,SS</sub> (low, middle, and high exposure). Cumulative incidence of BM progression or development and overall survival were determined for each group.</p></div><div><h3>Results</h3><p>A total of 173 patients were included, with 49 (28.3%) had baseline BM. Of these patients, 36.7% experienced BM progression, of which 16.7% in the low (&lt;159.3 ng/mL), 40.0% in the middle, and 47.1% in the high (&gt;270.7 ng/mL) C<sub>min,SS</sub> subgroups. After 12 months, the cumulative incidence of BM progression for the BM cohort was 20% (95% confidence interval [CI] 2.6–49.0), 31% (95% CI:10.6–53.9), and 31% (95% CI:10.8–54.5) per C<sub>min,SS</sub> subgroup, respectively. After 20 months, this was 20% (95% CI:2.6–49.0), 52% (95% CI:23.8–74.2), and 57% (95% CI:24.9–79.7), respectively. For the no or unknown BM cohort, 4.0% developed BM without differences within C<sub>min,SS</sub> subgroups.</p></div><div><h3>Conclusions</h3><p>No relation was found between osimertinib C<sub>min,SS</sub> and BM development or progression in patients with advanced <em>EGFR</em>m<em>+</em> NSCLC. This suggests that systemic osimertinib exposure is not a surrogate marker for BM development or progression.</p></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666364324000262/pdfft?md5=a80aff0e7fabe98c2bffb809b20caea9&pid=1-s2.0-S2666364324000262-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140180174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunotherapy With Radiotherapy for Brain Metastases in Patients With NSCLC: NEJ060 免疫疗法配合放疗治疗 NSCLC 患者的脑转移瘤:NEJ060
Q3 Medicine Pub Date : 2024-02-20 DOI: 10.1016/j.jtocrr.2024.100655
Takehiro Tozuka MD , Yuji Minegishi MD, PhD , Ou Yamaguchi MD, PhD , Kana Watanabe MD , Yukihiro Toi MD , Ryota Saito MD, PhD , Yoshiaki Nagai MD, PhD , Yosuke Tamura MD, PhD , Tetsuaki Shoji MD, PhD , Haruka Odagiri MD , Noriyuki Ebi MD , Kosuke Sakai MD, PhD , Nobuhiro Kanaji MD, PhD , Makoto Izumi MD , Sayo Soda MD, PhD , Satoshi Watanabe MD, PhD , Satoshi Morita PhD , Kunihiko Kobayashi MD, PhD , Masahiro Seike MD, PhD

Introduction

Immune checkpoint inhibitor (ICI)–based treatment has become standard treatment for patients with advanced NSCLC. We aimed to determine the survival benefit of upfront radiotherapy for brain metastases (BMs) in patients with NSCLC who received ICI alone (ICI-alone) or with chemotherapy (ICI-chemo).

Methods

This study included consecutive patients with NSCLC having BMs who received ICI alone or ICI-chemo at 50 institutes between February 2017 and September 2021. The presence of BMs was confirmed by imaging before treatment. Treatment outcomes were compared between patients who did and did not receive upfront radiotherapy for BMs. Potential confounding factors were adjusted between the groups through inverse probability treatment weighting (IPTW) analysis and overlap weighting (OW) analysis with propensity scores.

Results

Patients were grouped as ICI-alone cohort, 224 patients (upfront-radiotherapy group, 135 patients; no-radiotherapy group, 89 patients) and ICI-chemo cohort, 367 patients (upfront-radiotherapy group, 212 patients; no-radiotherapy group, 155 patients). In the ICI-alone cohort, the overall survival of the upfront-radiotherapy group was significantly longer than that of the no-radiotherapy group (IPTW-adjusted hazards ratio [HR] = 0.45 [95% confidence interval [CI]: 0.29–0.72], OW-adjusted HR = 0.52 [95% CI: 0.35–0.77]). In contrast, in the ICI-chemo cohort, the OS of the upfront-radiotherapy group was not significantly different from that of the no-radiotherapy group (IPTW-adjusted HR = 1.02 [95% CI: 0.70–1.48], OW-adjusted HR = 0.93 [95% CI: 0.65–1.33]).

Conclusions

Upfront radiotherapy for BMs was associated with longer overall survival in patients with NSCLC who received ICI alone; however, it did not exhibit survival benefits in the patients who received ICI-chemo.

简介基于免疫检查点抑制剂(ICI)的治疗已成为晚期NSCLC患者的标准治疗方法。我们旨在确定单独接受ICI治疗(ICI-alone)或联合化疗(ICI-chemo)的NSCLC患者脑转移瘤(BMs)前期放疗的生存获益。治疗前通过影像学检查确认是否存在BMs。比较了因BMs而接受和未接受前期放疗的患者的治疗结果。通过逆概率治疗加权(IPTW)分析和带有倾向分数的重叠加权(OW)分析对各组间的潜在混杂因素进行了调整。结果患者被分为ICI-单独队列224例(前期放疗组,135例;无放疗组,89例)和ICI-化疗队列367例(前期放疗组,212例;无放疗组,155例)。在 ICI 单药队列中,前期放疗组的总生存期明显长于无放疗组(IPTW 调整后的危险比 [HR] = 0.45 [95% 置信区间 [CI]:0.29-0.72],OW 调整后的 HR = 0.52 [95% CI:0.35-0.77])。相比之下,在ICI-化疗队列中,前期放疗组的OS与无放疗组无显著差异(IPTW调整后HR = 1.02 [95% CI: 0.70-1.48],OW调整后HR = 0.93 [95% CI: 0.65-1.33]).结论Upfront放疗治疗BMs与单独接受ICI治疗的NSCLC患者总生存期延长相关;但在接受ICI-化疗的患者中并未表现出生存获益。
{"title":"Immunotherapy With Radiotherapy for Brain Metastases in Patients With NSCLC: NEJ060","authors":"Takehiro Tozuka MD ,&nbsp;Yuji Minegishi MD, PhD ,&nbsp;Ou Yamaguchi MD, PhD ,&nbsp;Kana Watanabe MD ,&nbsp;Yukihiro Toi MD ,&nbsp;Ryota Saito MD, PhD ,&nbsp;Yoshiaki Nagai MD, PhD ,&nbsp;Yosuke Tamura MD, PhD ,&nbsp;Tetsuaki Shoji MD, PhD ,&nbsp;Haruka Odagiri MD ,&nbsp;Noriyuki Ebi MD ,&nbsp;Kosuke Sakai MD, PhD ,&nbsp;Nobuhiro Kanaji MD, PhD ,&nbsp;Makoto Izumi MD ,&nbsp;Sayo Soda MD, PhD ,&nbsp;Satoshi Watanabe MD, PhD ,&nbsp;Satoshi Morita PhD ,&nbsp;Kunihiko Kobayashi MD, PhD ,&nbsp;Masahiro Seike MD, PhD","doi":"10.1016/j.jtocrr.2024.100655","DOIUrl":"https://doi.org/10.1016/j.jtocrr.2024.100655","url":null,"abstract":"<div><h3>Introduction</h3><p>Immune checkpoint inhibitor (ICI)–based treatment has become standard treatment for patients with advanced NSCLC. We aimed to determine the survival benefit of upfront radiotherapy for brain metastases (BMs) in patients with NSCLC who received ICI alone (ICI-alone) or with chemotherapy (ICI-chemo).</p></div><div><h3>Methods</h3><p>This study included consecutive patients with NSCLC having BMs who received ICI alone or ICI-chemo at 50 institutes between February 2017 and September 2021. The presence of BMs was confirmed by imaging before treatment. Treatment outcomes were compared between patients who did and did not receive upfront radiotherapy for BMs. Potential confounding factors were adjusted between the groups through inverse probability treatment weighting (IPTW) analysis and overlap weighting (OW) analysis with propensity scores.</p></div><div><h3>Results</h3><p>Patients were grouped as ICI-alone cohort, 224 patients (upfront-radiotherapy group, 135 patients; no-radiotherapy group, 89 patients) and ICI-chemo cohort, 367 patients (upfront-radiotherapy group, 212 patients; no-radiotherapy group, 155 patients). In the ICI-alone cohort, the overall survival of the upfront-radiotherapy group was significantly longer than that of the no-radiotherapy group (IPTW-adjusted hazards ratio [HR] = 0.45 [95% confidence interval [CI]: 0.29–0.72], OW-adjusted HR = 0.52 [95% CI: 0.35–0.77]). In contrast, in the ICI-chemo cohort, the OS of the upfront-radiotherapy group was not significantly different from that of the no-radiotherapy group (IPTW-adjusted HR = 1.02 [95% CI: 0.70–1.48], OW-adjusted HR = 0.93 [95% CI: 0.65–1.33]).</p></div><div><h3>Conclusions</h3><p>Upfront radiotherapy for BMs was associated with longer overall survival in patients with NSCLC who received ICI alone; however, it did not exhibit survival benefits in the patients who received ICI-chemo.</p></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666364324000250/pdfft?md5=347b3200c1c497c4800c5752fb07e40f&pid=1-s2.0-S2666364324000250-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140163116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adenocarcinoma Harboring EGFR-RAD51 Fusion Treated With Osimertinib: A Case Report 奥希替尼治疗表皮生长因子受体-RAD51融合的腺癌:病例报告
Q3 Medicine Pub Date : 2024-02-19 DOI: 10.1016/j.jtocrr.2024.100652
Sunny Y. Lai MD, Noah H. Richardson MD, Mya Tran PharmD, Nasser H. Hanna MD, Misty D. Shields MD, PhD

EGFR mutations are among the most common driver mutations in lung adenocarcinoma. Rare alterations, such as the EGFR-RAD51 fusion, respond to treatment with EGFR tyrosine kinase inhibitors but can be missed by limited genomic sequencing panels. Here, we report a case of metastatic lung adenocarcinoma in a never-smoker patient who initially did not have a targetable alteration identified on two different sequencing panels. The initial response to combination chemoimmunotherapy was short-lived. A rare EGFR-RAD51 fusion was then identified using a more in-depth sequencing panel. The patient experienced a dramatic and durable response to osimertinib. This case highlights the rarity of EGFR-RAD51 fusions, the efficacy of EGFR tyrosine kinase inhibitors, and the importance of a thorough search for targetable alterations in never-smokers with lung adenocarcinoma.

表皮生长因子受体突变是肺腺癌最常见的驱动突变之一。表皮生长因子受体-RAD51融合等罕见突变对表皮生长因子受体酪氨酸激酶抑制剂的治疗有反应,但可能被有限的基因组测序面板所遗漏。在此,我们报告了一例从未吸烟的转移性肺腺癌患者的病例,该患者最初在两个不同的测序板上均未发现可靶向的改变。患者最初对联合化疗免疫疗法的反应很短暂。随后,通过一个更深入的测序面板发现了罕见的表皮生长因子受体-RAD51融合。患者对奥希替尼产生了显著而持久的反应。该病例凸显了表皮生长因子受体-RAD51融合的罕见性、表皮生长因子受体酪氨酸激酶抑制剂的疗效,以及在从未吸烟的肺腺癌患者中彻底寻找靶向性改变的重要性。
{"title":"Adenocarcinoma Harboring EGFR-RAD51 Fusion Treated With Osimertinib: A Case Report","authors":"Sunny Y. Lai MD,&nbsp;Noah H. Richardson MD,&nbsp;Mya Tran PharmD,&nbsp;Nasser H. Hanna MD,&nbsp;Misty D. Shields MD, PhD","doi":"10.1016/j.jtocrr.2024.100652","DOIUrl":"https://doi.org/10.1016/j.jtocrr.2024.100652","url":null,"abstract":"<div><p><em>EGFR</em> mutations are among the most common driver mutations in lung adenocarcinoma. Rare alterations, such as the <em>EGFR-RAD51</em> fusion, respond to treatment with EGFR tyrosine kinase inhibitors but can be missed by limited genomic sequencing panels. Here, we report a case of metastatic lung adenocarcinoma in a never-smoker patient who initially did not have a targetable alteration identified on two different sequencing panels. The initial response to combination chemoimmunotherapy was short-lived. A rare <em>EGFR-RAD51</em> fusion was then identified using a more in-depth sequencing panel. The patient experienced a dramatic and durable response to osimertinib. This case highlights the rarity of <em>EGFR-RAD51</em> fusions, the efficacy of EGFR tyrosine kinase inhibitors, and the importance of a thorough search for targetable alterations in never-smokers with lung adenocarcinoma.</p></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666364324000225/pdfft?md5=6fe60be7fd389bf5543280384dcab5de&pid=1-s2.0-S2666364324000225-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140141824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cabozantinib Response in a Patient With NSCLC Harboring Both MET Exon 14 Skipping Mutation and Secondary RET Fusion: A Case Report 卡博替尼对同时携带 MET 第 14 号外显子跳越突变和继发性 RET 融合的 NSCLC 患者的应答:病例报告
Q3 Medicine Pub Date : 2024-02-07 DOI: 10.1016/j.jtocrr.2024.100647
Carlos Torrado MD , Jamie Feng MD, FRCPC , Elizabeth Faour MD, FRCPC , Natasha B. Leighl MD, MMSc, FRCPC, FASCO

MET exon 14 skipping mutation has emerged as a new oncogenic driver in NSCLC with available targeted therapies, including Food and Drug Administration–approved inhibitors capmatinib and tepotinib. Potential resistance mechanisms are beginning to be described and include several on-target and off-target mutations. Here, we report an emergent secondary RET fusion in a patient with a primary MET exon 14 skipping mutation that progressed on capmatinib after the initial response. Subsequently, this patient received both a RET inhibitor (selpercatinib) followed by another MET-targeted treatment (tepotinib) without clinical benefit. Thereafter, cabozantinib, a multikinase inhibitor with activity against RET and MET was started with a rapid clinical and radiologic benefit.

MET第14外显子跳越突变已成为NSCLC新的致癌驱动因素,现有的靶向疗法包括美国食品药品管理局批准的抑制剂卡马替尼和泰泊替尼。目前已开始描述潜在的耐药机制,包括几种靶上和靶下突变。在此,我们报告了一名原发性 MET 14 号外显子跳越突变患者出现的继发性 RET 融合,该患者在服用卡马替尼后出现了初步应答,但病情有所进展。随后,该患者同时接受了一种 RET 抑制剂(赛铂替尼)和另一种 MET 靶向治疗(替泊替尼),但均未获得临床获益。此后,该患者开始接受卡博替尼(一种对RET和MET具有活性的多激酶抑制剂)治疗,并迅速获得了临床和放射学疗效。
{"title":"Cabozantinib Response in a Patient With NSCLC Harboring Both MET Exon 14 Skipping Mutation and Secondary RET Fusion: A Case Report","authors":"Carlos Torrado MD ,&nbsp;Jamie Feng MD, FRCPC ,&nbsp;Elizabeth Faour MD, FRCPC ,&nbsp;Natasha B. Leighl MD, MMSc, FRCPC, FASCO","doi":"10.1016/j.jtocrr.2024.100647","DOIUrl":"https://doi.org/10.1016/j.jtocrr.2024.100647","url":null,"abstract":"<div><p>MET exon 14 skipping mutation has emerged as a new oncogenic driver in NSCLC with available targeted therapies, including Food and Drug Administration–approved inhibitors capmatinib and tepotinib. Potential resistance mechanisms are beginning to be described and include several on-target and off-target mutations. Here, we report an emergent secondary RET fusion in a patient with a primary MET exon 14 skipping mutation that progressed on capmatinib after the initial response. Subsequently, this patient received both a RET inhibitor (selpercatinib) followed by another MET-targeted treatment (tepotinib) without clinical benefit. Thereafter, cabozantinib, a multikinase inhibitor with activity against RET and MET was started with a rapid clinical and radiologic benefit.</p></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666364324000171/pdfft?md5=873c3988b4ea93bcebc85f563c2e0064&pid=1-s2.0-S2666364324000171-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140195513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Health Services Access Inequalities in Brazil Result in Poorer Outcomes for Stage III NSCLC—RELANCE/LACOG 0118 巴西医疗服务获取不平等导致 III 期 NSCLC 治疗效果较差 - RELANCE/LACOG 0118
Q3 Medicine Pub Date : 2024-02-03 DOI: 10.1016/j.jtocrr.2024.100646
Vladmir C. Cordeiro de Lima MD, PhD , Ana Gelatti MD, MSc , José F.P. Moura MD, PhD , Aline F. Fares MD, MSc , Gilberto de Castro Jr. MD, PhD , Clarissa Mathias MD, PhD , Ricardo M. Terra MD, PhD , Gustavo Werutsky MD, PhD , Marcelo Corassa MD , Luiz Henrique L. Araújo MD, PhD , Eduardo Cronenberger MD, MSc , Fernanda K. Fujiki MD , Sandro Reichow MD , Antônio Vinícius T. da Silva MD , Tércia V. Reis MD , Mônica Luciana A. Padoan MD , Patrícia Pacheco MD , Rosely Yamamura MD , Caroline Kawamura MD , Eldsamira Mascarenhas MD, MSc , Clarissa Baldotto MD, PhD

Introduction

Stage III NSCLC is a heterogeneous disease, representing approximately one-third of newly diagnosed lung cancers. Brazil lacks detailed information regarding stage distribution, treatment patterns, survival, and prognostic variables in locally advanced NSCLC.

Methods

RELANCE/LACOG 0118 is an observational, retrospective cohort study assessing sociodemographic and clinical data of patients diagnosed with having stage III NSCLC from January 2015 to June 2019, regardless of treatment received. The study was conducted across 13 cancer centers in Brazil. Disease status and survival data were collected up to June 2021. Descriptive statistics, survival analyses, and a multivariable Cox regression model were performed. p values less than 0.05 were considered significant.

Results

We recruited 403 patients with stage III NSCLC. Most were male (64.0%), White (31.5%), and smokers or former smokers (86.1%). Most patients had public health insurance (67.5%), had stage IIIA disease (63.2%), and were treated with concurrent chemoradiation (53.1%). The median follow-up time was 33.83 months (95% confidence interval [CI]: 30.43–37.50). Median overall survival (OS) was 27.97 months (95% CI: 21.57–31.73), and median progression-free survival was 11.23 months (95% CI: 10.70–12.77). The type of treatment was independently associated with OS and progression-free survival, whereas the types of health insurance and histology were independent predictors of OS only.

Conclusions

Brazilian patients with stage III NSCLC with public health insurance are diagnosed later and have poorer OS. Nevertheless, patients with access to adequate treatment have outcomes similar to those reported in the pivotal trials. Health policy should be improved to make lung cancer diagnosis faster and guarantee prompt access to adequate treatment in Brazil.

导言 III 期 NSCLC 是一种异质性疾病,约占新诊断肺癌的三分之一。方法RELANCE/LACOG 0118是一项观察性、回顾性队列研究,评估2015年1月至2019年6月期间确诊为III期NSCLC患者的社会人口学和临床数据,无论患者接受何种治疗。该研究在巴西的 13 个癌症中心进行。疾病状态和生存数据收集至 2021 年 6 月。结果我们招募了403名III期NSCLC患者。大多数患者为男性(64.0%)、白人(31.5%)、吸烟者或曾经吸烟者(86.1%)。大多数患者有公共医疗保险(67.5%),疾病为 IIIA 期(63.2%),同时接受化疗和放疗(53.1%)。中位随访时间为 33.83 个月(95% 置信区间 [CI]:30.43-37.50)。中位总生存期(OS)为 27.97 个月(95% 置信区间:21.57-31.73),中位无进展生存期为 11.23 个月(95% 置信区间:10.70-12.77)。治疗类型与OS和无进展生存期独立相关,而医疗保险类型和组织学仅是OS的独立预测因素。尽管如此,能够获得适当治疗的患者的疗效与关键试验报告的结果相似。巴西应改进医疗政策,加快肺癌诊断速度,确保患者能及时获得适当的治疗。
{"title":"Health Services Access Inequalities in Brazil Result in Poorer Outcomes for Stage III NSCLC—RELANCE/LACOG 0118","authors":"Vladmir C. Cordeiro de Lima MD, PhD ,&nbsp;Ana Gelatti MD, MSc ,&nbsp;José F.P. Moura MD, PhD ,&nbsp;Aline F. Fares MD, MSc ,&nbsp;Gilberto de Castro Jr. MD, PhD ,&nbsp;Clarissa Mathias MD, PhD ,&nbsp;Ricardo M. Terra MD, PhD ,&nbsp;Gustavo Werutsky MD, PhD ,&nbsp;Marcelo Corassa MD ,&nbsp;Luiz Henrique L. Araújo MD, PhD ,&nbsp;Eduardo Cronenberger MD, MSc ,&nbsp;Fernanda K. Fujiki MD ,&nbsp;Sandro Reichow MD ,&nbsp;Antônio Vinícius T. da Silva MD ,&nbsp;Tércia V. Reis MD ,&nbsp;Mônica Luciana A. Padoan MD ,&nbsp;Patrícia Pacheco MD ,&nbsp;Rosely Yamamura MD ,&nbsp;Caroline Kawamura MD ,&nbsp;Eldsamira Mascarenhas MD, MSc ,&nbsp;Clarissa Baldotto MD, PhD","doi":"10.1016/j.jtocrr.2024.100646","DOIUrl":"10.1016/j.jtocrr.2024.100646","url":null,"abstract":"<div><h3>Introduction</h3><p>Stage III NSCLC is a heterogeneous disease, representing approximately one-third of newly diagnosed lung cancers. Brazil lacks detailed information regarding stage distribution, treatment patterns, survival, and prognostic variables in locally advanced NSCLC.</p></div><div><h3>Methods</h3><p>RELANCE/LACOG 0118 is an observational, retrospective cohort study assessing sociodemographic and clinical data of patients diagnosed with having stage III NSCLC from January 2015 to June 2019, regardless of treatment received. The study was conducted across 13 cancer centers in Brazil. Disease status and survival data were collected up to June 2021. Descriptive statistics, survival analyses, and a multivariable Cox regression model were performed. <em>p</em> values less than 0.05 were considered significant.</p></div><div><h3>Results</h3><p>We recruited 403 patients with stage III NSCLC. Most were male (64.0%), White (31.5%), and smokers or former smokers (86.1%). Most patients had public health insurance (67.5%), had stage IIIA disease (63.2%), and were treated with concurrent chemoradiation (53.1%). The median follow-up time was 33.83 months (95% confidence interval [CI]: 30.43–37.50). Median overall survival (OS) was 27.97 months (95% CI: 21.57–31.73), and median progression-free survival was 11.23 months (95% CI: 10.70–12.77). The type of treatment was independently associated with OS and progression-free survival, whereas the types of health insurance and histology were independent predictors of OS only.</p></div><div><h3>Conclusions</h3><p>Brazilian patients with stage III NSCLC with public health insurance are diagnosed later and have poorer OS. Nevertheless, patients with access to adequate treatment have outcomes similar to those reported in the pivotal trials. Health policy should be improved to make lung cancer diagnosis faster and guarantee prompt access to adequate treatment in Brazil.</p></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266636432400016X/pdfft?md5=57c47047bb2b8edb7d9c4b08d8eae3c3&pid=1-s2.0-S266636432400016X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139686193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
JTO Clinical and Research Reports
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1